Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Kottwitz

Urology Evansville, IN Medical Doctor

NPI 1508204454 CMS profile 377522

920 S Hebron Ave, Evansville, IN 47714

Open in the dashboard

General payments

$3,613

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Kottwitz of Evansville, IN is reported in the CMS Open Payments database as having received $3,613 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $267 7
2024 General $152 3
2023 General $1,109 11
2022 General $346 4
2021 General $220 4
2020 General $235 12
2019 General $1,284 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Kottwitz
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Kottwitz were reported at $267. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Kottwitz Urology median Middle half National median
2019 $1,284 $480 $147–$1,201 $163
2020 $235 $246 $87–$645 $114
2021 $220 $358 $111–$1,000 $132
2022 $346 $476 $143–$1,263 $149
2023 $1,109 $560 $168–$1,461 $160
2024 $152 $563 $170–$1,464 $164
2025 $267 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $868 15 payments
  2. Valencia Technologies Corporation $631 2 payments
  3. Cook Medical LLC $485 6 payments
  4. Astellas Pharma US Inc $388 15 payments
  5. PROCEPT BioRobotics Corporation $194 2 payments
  6. Janssen Biotech, Inc. $193 8 payments
  7. Teleflex LLC $114 4 payments
  8. Axonics Modulation Technologies, Inc. $110 1 payment
  9. Medtronic, Inc. $98 4 payments
  10. Laborie Medical Technologies Corp. $86 2 payments
  11. Other $446 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,791 81 payments
  2. Travel and Lodging $633 3 payments
  3. Education $189 2 payments
Products named General payments · program years 2019–2025
  1. eCoin Device Kit $631 2 payments
  2. AMS $201 3 payments
  3. XTANDI $177 12 payments
  4. ERLEADA $151 7 payments
  5. NGage $136 1 payment
  6. LITHO 150 $135 2 payments
  7. Tria Firm $134 1 payment
  8. AQUABEAM ROBOTIC SYSTEM $128 1 payment
  9. REZUM $122 3 payments
  10. Cook Medical Stents $120 1 payment
  11. Other $1,761 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

753

Median for Urology: 1,053

Drug cost

$68,619

Median for Urology: $101,464

Branded share of claims

31.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 71 $47,437
Myrbetriq Mirabegron Brand 24 $10,669
Tamsulosin Hcl Generic 300 $3,268
Solifenacin Succinate Generic 28 $1,620
Testosterone Cypionate Generic 20 $926
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 49 $888
Potassium Citrate Er Potassium Citrate Brand 22 $793
Estradiol Generic 14 $786
Methenamine Hippurate Generic 15 $564
Alfuzosin Hcl Er Alfuzosin Hcl Brand 16 $298

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$91,438

Of which drugs: $7,867

Medicare patients

302

Average age 75

Services billed

1,807

85 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 33%
Diabetes 32%
Atrial fibrillation 28%
Chronic kidney disease 26%
Cancer 25%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record